WallStreetZenWallStreetZen

NASDAQ: EYEN
Eyenovia Inc Stock Forecast, Predictions & Price Target

Open Broker Account

Analyst price target for EYEN

Based on 1 analyst offering 12 month price targets for Eyenovia Inc.
Min Forecast
$12.00+393.83%
Avg Forecast
$12.00+393.83%
Max Forecast
$12.00+393.83%

Should I buy or sell EYEN stock?

Based on 1 analyst offering ratings for Eyenovia Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their EYEN stock forecasts and price targets.

EYEN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
HC Wainwright & Co.
Top 29%
72
BuyInitiates Coverage On$12.00+393.83%2022-10-05

1 of 1

Forecast return on equity

Is EYEN forecast to generate an efficient return?
Company
20.29%
Industry
22.46%
Market
122.06%
EYEN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is EYEN forecast to generate an efficient return on assets?
Company
13.45%
Industry
13.57%
EYEN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

EYEN earnings per share forecast

What is EYEN's earnings per share in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
-$0.81
Avg 2 year Forecast
-$0.79
Avg 3 year Forecast
-$0.27

EYEN revenue forecast

What is EYEN's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$1.9M-81%
Avg 2 year Forecast
$10.0M+0%
Avg 3 year Forecast
$46.5M+364.75%
EYEN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

EYEN revenue growth forecast

How is EYEN forecast to perform vs Biotechnology companies and vs the US market?
Company
61.02%
Industry
23.83%
Market
8.53%
EYEN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
EYEN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

EYEN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
EYEN$2.43$12.00+393.83%Buy
NXTC$3.00$14.50+383.33%Strong Buy
CLSD$1.37$7.50+447.45%Buy
LIFE$2.88$22.75+689.93%Strong Buy
DARE$0.99$6.00+506.06%Buy

Eyenovia Stock Forecast FAQ

Is Eyenovia Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: EYEN) stock is to Buy EYEN stock.

Out of 1 analyst, 0 (0%) are recommending EYEN as a Strong Buy, 1 (100%) are recommending EYEN as a Buy, 0 (0%) are recommending EYEN as a Hold, 0 (0%) are recommending EYEN as a Sell, and 0 (0%) are recommending EYEN as a Strong Sell.

If you're new to stock investing, here's how to buy Eyenovia stock.

What is EYEN's earnings growth forecast for 2022-2024?

(NASDAQ: EYEN) Eyenovia's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 8.86%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.88%.

Eyenovia's earnings in 2022 is -$17,164,085.On average, 2 Wall Street analysts forecast EYEN's earnings for 2022 to be -$27,712,418, with the lowest EYEN earnings forecast at -$29,423,061, and the highest EYEN earnings forecast at -$25,659,647. On average, 2 Wall Street analysts forecast EYEN's earnings for 2023 to be -$27,028,161, with the lowest EYEN earnings forecast at -$27,028,161, and the highest EYEN earnings forecast at -$26,686,032.

In 2024, EYEN is forecast to generate -$9,237,473 in earnings, with the lowest earnings forecast at -$9,237,473 and the highest earnings forecast at -$9,237,473.

What is EYEN's revenue growth forecast for 2022-2024?

(NASDAQ: EYEN) Eyenovia's forecast annual revenue growth rate of 61.02% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 23.83%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 8.53%.

Eyenovia's revenue in 2022 is $10,000,000.On average, 1 Wall Street analysts forecast EYEN's revenue for 2022 to be $65,004,438, with the lowest EYEN revenue forecast at $65,004,438, and the highest EYEN revenue forecast at $65,004,438. On average, 1 Wall Street analysts forecast EYEN's revenue for 2023 to be $342,128,620, with the lowest EYEN revenue forecast at $342,128,620, and the highest EYEN revenue forecast at $342,128,620.

In 2024, EYEN is forecast to generate $1,590,042,761 in revenue, with the lowest revenue forecast at $1,590,042,761 and the highest revenue forecast at $1,590,042,761.

What is EYEN's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: EYEN) forecast ROA is 13.45%, which is lower than the forecast US Biotechnology industry average of 13.57%.

What is EYEN's Price Target?

According to 1 Wall Street analyst that have issued a 1 year EYEN price target, the average EYEN price target is $12.00, with the highest EYEN stock price forecast at $12.00 and the lowest EYEN stock price forecast at $12.00.

The Wall Street analyst predicted that Eyenovia's share price could reach $12.00 by Oct 5, 2023. The average Eyenovia stock price prediction forecasts a potential upside of 393.83% from the current EYEN share price of $2.43.

What is EYEN's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: EYEN) Eyenovia's current Earnings Per Share (EPS) is -$0.55. On average, analysts forecast that EYEN's EPS will be -$0.81 for 2022, with the lowest EPS forecast at -$0.86, and the highest EPS forecast at -$0.75. On average, analysts forecast that EYEN's EPS will be -$0.79 for 2023, with the lowest EPS forecast at -$0.79, and the highest EPS forecast at -$0.78. In 2024, EYEN's EPS is forecast to hit -$0.27 (min: -$0.27, max: -$0.27).

What is EYEN's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: EYEN) forecast ROE is 20.29%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.